Imaging Endpoints Grows Executive Team: Jatinder Kaur Joins as VP of Imaging Operations and Yi Zhu Joins as Director of Imaging Operations

Imaging Endpoints of Scottsdale, Arizona is proud to announce two new additions to their executive team.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Scottsdale, AZ (PRWEB) April 28, 2014

Imaging Endpoints LLC, a rapidly growing imaging research and core laboratory (iCRO) for Phase I-III clinical trials, is proud to announce the April, 2014 additions to their executive team. Jatinder Kaur, BS, MS, has joined as Vice President of Imaging Operations, responsible for overseeing all clinical imaging activities at the Company. Jatinder has over 11 years of clinical trials experience and extensive expertise in imaging CRO services. Yi Zhu, MD, MBA, is the new Director of Imaging Operations and will leverage more than 14 years of clinical trial and imaging experience to directly manage the operations team at Imaging Endpoints.

“Imaging Endpoints is expanding its staff to help accommodate the company’s accelerating growth, in both early and late stage clinical trials. Both Mrs. Jatinder and Yi will work together to manage and grow the imaging operations team at Imaging Endpoints which currently consists of 40 in-house radiologists, project managers, radiology technologists, and project coordinators. They will also help us leverage our proprietary imaging technologies, such as Quantitative Textural Analysis or Macrophage Imaging, to help pharmaceutical and biotech companies evaluate their agent and design targeted Phase II studies,” commented Dr. Ron Korn, Founder, Chairman and Chief Medical Officer at Imaging Endpoints.

Jatinder Kaur joins Imaging Endpoints from Intrinsic Imaging, where she helped build the Company from the ground-up serving most recently as Vice President and prior to that as the Senior Director of Imaging Operations. Before her tenure at Intrinsic Imaging, Jatinder worked as the Director of the Product Management Group at Perceptive Informatics (PAREXEL) in Billerica, Massachusetts.

Dr. Yi Zhu has managed many imaging projects in Phase I-III clinical trials. Before joining Imaging Endpoints, Yi helped build and grow the imaging core lab at the American College Radiology Image Metrix and most recently served as Senior Manager of Clinical Operations. Prior to Image Metrics Dr. Zhu was a Clinical Project Leader at Sanofi-Aventis Pharmaceutical Company.

“We are very pleased to have Jatinder and Yi on-board as we expand our track record of success; all sponsors that have tried our services have continued to use us for their subsequent imaging needs. Ms. Kaur and Dr. Zhu will be instrumental in helping us continue the rapid growth of our clinical trials business where we are becoming widely recognized for our in-house radiologists expertise and our ability to perform real-time reads for Phase II and III trials globally,” commented Doug Dean Burkett, CEO and President at Imaging Endpoints.

About Imaging Endpoints (IE): Imaging Endpoints is an Imaging Research and Core Laboratory based in Scottsdale, Arizona. We are an affiliate of Scottsdale Healthcare, home to the Virginia G Piper Cancer Center and one of the largest healthcare systems nationally. We are also an affiliate of Scottsdale Medical Imaging Limited (SMIL), ranked as the one of the largest private radiology groups in the US. We are a rapidly growing specialty iCRO with exquisite technology, expertise and service. Imaging Endpoints provides imaging research expertise and services in early stage clinical trials and comprehensive iCRO services for Phase II and III trials, providing real-time reads for clinical trials globally.

About IE’s Quantitative Textural Analysis (QTA): QTA is a post processing technique offered by Imaging Endpoints through an exclusive arrangement with TexRAD. QTA is used to quantify changes in tissue and tumor heterogeneity from standard-of-care CT scans by assessing the distribution of textural features within a lesion and its change following treatment. Nearly forty publications and in-house data have shown that this information is associated with underlying tumor biology and treatment response.

For more information on Imaging Endpoints and its services please visit http://www.imagingendpoints.com.

If you wish to discuss your development needs or find out which of our services can help you achieve your goals, please call our offices at (480) 314-3070, or send an email to info(at)imagingendpoints(dot)com


Contact